CR20230427A - Compuestos inhibidores de fgfr3 - Google Patents
Compuestos inhibidores de fgfr3Info
- Publication number
- CR20230427A CR20230427A CR20230427A CR20230427A CR20230427A CR 20230427 A CR20230427 A CR 20230427A CR 20230427 A CR20230427 A CR 20230427A CR 20230427 A CR20230427 A CR 20230427A CR 20230427 A CR20230427 A CR 20230427A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fgfr3
- inhibiting compounds
- achondroplasia
- fibrosis
- saddan
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 title 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000008919 achondroplasia Diseases 0.000 abstract 3
- 201000001079 SADDAN Diseases 0.000 abstract 2
- 208000017601 Severe achondroplasia-developmental delay-acanthosis nigricans syndrome Diseases 0.000 abstract 2
- 206010008723 Chondrodystrophy Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000007326 Muenke Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 201000003896 thanatophoric dysplasia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona los compuestos de la fórmula: <!--[if gte mso 9]><xml> <o:OLEObject Type="Embed" ProgID="MDLDrawOLE.MDLDrawObject.1" ShapeID="_x0000_i1025" DrawAspect="Content" ObjectID="_1754985866"> </o:OLEObject></xml><![endif]-->, para uso en el tratamiento de la esclerosis sistémica, la fibrosis (p. ej., fibrosis pulmonar), la acondroplasia, la displasia tanatofórica (p. ej., tipo I), la acondroplasia grave con retraso del desarrollo y acantosis nigricans (SADDAN), el síndrome de Muenke o el cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156527P | 2021-03-04 | 2021-03-04 | |
| PCT/US2022/018644 WO2022187443A1 (en) | 2021-03-04 | 2022-03-03 | Fgfr3 inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230427A true CR20230427A (es) | 2023-09-26 |
Family
ID=80937162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230427A CR20230427A (es) | 2021-03-04 | 2022-03-03 | Compuestos inhibidores de fgfr3 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US11878976B2 (es) |
| EP (1) | EP4301468B1 (es) |
| JP (2) | JP7480438B2 (es) |
| KR (2) | KR20240148943A (es) |
| CN (1) | CN117120439B (es) |
| AR (1) | AR125588A1 (es) |
| AU (1) | AU2022229380B2 (es) |
| BR (1) | BR112023015519A2 (es) |
| CA (1) | CA3210594A1 (es) |
| CL (1) | CL2023002605A1 (es) |
| CO (1) | CO2023011623A2 (es) |
| CR (1) | CR20230427A (es) |
| DK (1) | DK4301468T3 (es) |
| DO (1) | DOP2023000176A (es) |
| EC (1) | ECSP23066654A (es) |
| ES (1) | ES3053601T3 (es) |
| FI (1) | FI4301468T3 (es) |
| HR (1) | HRP20251473T1 (es) |
| IL (1) | IL304886B2 (es) |
| JO (1) | JOP20230206A1 (es) |
| LT (1) | LT4301468T (es) |
| MA (1) | MA63601B1 (es) |
| MD (1) | MD4301468T2 (es) |
| MX (1) | MX2023010342A (es) |
| PE (1) | PE20231563A1 (es) |
| PT (1) | PT4301468T (es) |
| RS (1) | RS67479B1 (es) |
| SI (1) | SI4301468T1 (es) |
| SM (1) | SMT202600089T1 (es) |
| TW (2) | TWI820622B (es) |
| UA (1) | UA130389C2 (es) |
| WO (1) | WO2022187443A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202302594A (zh) | 2021-03-04 | 2023-01-16 | 美商胞質動力學公司 | 心臟肌節抑制劑 |
| TWI820622B (zh) * | 2021-03-04 | 2023-11-01 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
| KR20250057022A (ko) * | 2022-09-07 | 2025-04-28 | 일라이 릴리 앤드 캄파니 | 4-[4-[3-클로로-4-[1-(2-피리딜)-2-히드록시-에톡시]피라졸로[1,5-a]피리딘-6-일]-5-메틸-트리아졸-1-일]피페리딘-1-카르보니트릴유도체와 갈산 및 니코틴아미드의 공-결정 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| WO2024117205A1 (ja) * | 2022-11-30 | 2024-06-06 | 北興化学工業株式会社 | 双環式ピリジン誘導体およびその塩、並びに、当該誘導体又はその塩を有効成分として含有することを特徴とする有害生物防除剤 |
| WO2024114680A1 (zh) * | 2022-11-30 | 2024-06-06 | 海南先声再明医药股份有限公司 | 杂环化合物、药物组合物及其应用 |
| WO2024137587A1 (en) * | 2022-12-19 | 2024-06-27 | Tyra Biosciences, Inc. | Fgfr3 inhibitor compounds |
| JP2026501820A (ja) * | 2023-01-10 | 2026-01-16 | コージェント バイオサイエンシーズ， インコーポレイテッド | Ｆｇｆｒ阻害剤の化合物 |
| JP2026510974A (ja) | 2023-03-20 | 2026-04-10 | アセンディス ファーマ グロース ディスオーダーズ エー／エス | 軟骨形成不全症のヒト対象における胸腰椎奇形の治療の方法 |
| AU2024319770A1 (en) * | 2023-08-07 | 2026-02-19 | Cogent Biosciences, Inc. | Compounds for fgfr inhibition |
| WO2025259519A1 (en) | 2024-06-13 | 2025-12-18 | Eli Lilly And Company | Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3) |
| WO2026027643A1 (en) | 2024-07-31 | 2026-02-05 | Onco3R Therapeutics Bv | Compounds and pharmaceutical compositions thereof for the treatment of diseases such as cancer |
| WO2026027726A1 (en) | 2024-07-31 | 2026-02-05 | Onco3R Therapeutics Bv | Compounds and pharmaceutical compositions thereof for the treatment of diseases such as cancer |
| WO2026027635A1 (en) * | 2024-07-31 | 2026-02-05 | Onco3R Therapeutics Bv | Compounds and pharmaceutical compositions thereof for the treatment of diseases such as cancer |
| WO2026037249A1 (zh) * | 2024-08-13 | 2026-02-19 | 海思科医药集团股份有限公司 | 取代杂环类衍生物及其用途 |
| CN120647648B (zh) * | 2024-09-24 | 2026-03-06 | 上海辉棵生物医药有限公司 | 新fgfr3抑制剂化合物 |
| WO2026084690A1 (en) | 2024-10-14 | 2026-04-23 | Eli Lilly And Company | Fgfr3 inhibitor dosing regimens for use in treating cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2320907A4 (en) * | 2008-08-05 | 2012-09-05 | Merck Sharp & Dohme | THERAPEUTIC COMPOUNDS |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| CN101833512A (zh) | 2010-04-22 | 2010-09-15 | 中兴通讯股份有限公司 | 一种内存回收方法及其装置 |
| WO2013055645A1 (en) | 2011-10-12 | 2013-04-18 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| NZ703495A (en) * | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| JP6159028B2 (ja) | 2013-07-31 | 2017-07-05 | ギリアード サイエンシーズ， インコーポレイテッド | Ｓｙｋ阻害剤 |
| GB201416754D0 (en) * | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| UA119701C2 (uk) | 2015-04-29 | 2019-07-25 | Вуксі Фортуне Фармасьютікал Ко., Лтд | Піримідинові сполуки як jak-інгібітори |
| US10538517B2 (en) * | 2015-05-22 | 2020-01-21 | Principia Biopharma, Inc. | Quinolone derivatives as FGFR inhibitors |
| EP3508482B1 (en) * | 2016-09-01 | 2020-12-16 | Nanjing Transthera Biosciences Co. Ltd. | Inhibitors of fibroblast growth factor receptor and use thereof |
| CN107315291B (zh) | 2017-07-19 | 2020-06-16 | 深圳市华星光电半导体显示技术有限公司 | 一种goa显示面板及goa显示装置 |
| EP3668858A1 (en) | 2017-08-14 | 2020-06-24 | Pfizer Inc | Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| WO2020135878A1 (zh) * | 2018-12-29 | 2020-07-02 | 南京明德新药研发有限公司 | 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物 |
| EP3985005A4 (en) * | 2019-06-14 | 2023-07-19 | CGeneTech (Suzhou, China) Co., Ltd. | FUSED RING COMPOUND AS DUAL FGFR AND VEGFR INHIBITOR |
| TWI820622B (zh) * | 2021-03-04 | 2023-11-01 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
-
2022
- 2022-03-02 TW TW111107515A patent/TWI820622B/zh active
- 2022-03-02 TW TW112137198A patent/TWI915684B/zh active
- 2022-03-02 AR ARP220100462A patent/AR125588A1/es unknown
- 2022-03-02 IL IL304886A patent/IL304886B2/en unknown
- 2022-03-03 WO PCT/US2022/018644 patent/WO2022187443A1/en not_active Ceased
- 2022-03-03 US US17/685,753 patent/US11878976B2/en active Active
- 2022-03-03 PT PT227126869T patent/PT4301468T/pt unknown
- 2022-03-03 CA CA3210594A patent/CA3210594A1/en active Pending
- 2022-03-03 ES ES22712686T patent/ES3053601T3/es active Active
- 2022-03-03 MA MA63601A patent/MA63601B1/fr unknown
- 2022-03-03 MD MDE20240050T patent/MD4301468T2/ro unknown
- 2022-03-03 JP JP2023530844A patent/JP7480438B2/ja active Active
- 2022-03-03 BR BR112023015519A patent/BR112023015519A2/pt unknown
- 2022-03-03 SI SI202230212T patent/SI4301468T1/sl unknown
- 2022-03-03 KR KR1020247032342A patent/KR20240148943A/ko active Pending
- 2022-03-03 RS RS20251216A patent/RS67479B1/sr unknown
- 2022-03-03 UA UAA202303626A patent/UA130389C2/uk unknown
- 2022-03-03 KR KR1020237029713A patent/KR102712801B1/ko active Active
- 2022-03-03 EP EP22712686.9A patent/EP4301468B1/en active Active
- 2022-03-03 AU AU2022229380A patent/AU2022229380B2/en active Active
- 2022-03-03 MX MX2023010342A patent/MX2023010342A/es unknown
- 2022-03-03 FI FIEP22712686.9T patent/FI4301468T3/fi active
- 2022-03-03 DK DK22712686.9T patent/DK4301468T3/da active
- 2022-03-03 HR HRP20251473TT patent/HRP20251473T1/hr unknown
- 2022-03-03 LT LTEPPCT/US2022/018644T patent/LT4301468T/lt unknown
- 2022-03-03 PE PE2023002463A patent/PE20231563A1/es unknown
- 2022-03-03 SM SM20260089T patent/SMT202600089T1/it unknown
- 2022-03-03 CR CR20230427A patent/CR20230427A/es unknown
- 2022-03-03 CN CN202280019076.1A patent/CN117120439B/zh active Active
-
2023
- 2023-09-01 CL CL2023002605A patent/CL2023002605A1/es unknown
- 2023-09-01 DO DO2023000176A patent/DOP2023000176A/es unknown
- 2023-09-01 CO CONC2023/0011623A patent/CO2023011623A2/es unknown
- 2023-09-04 EC ECSENADI202366654A patent/ECSP23066654A/es unknown
- 2023-09-04 JO JOJO/P/2023/0206A patent/JOP20230206A1/ar unknown
- 2023-12-13 US US18/538,505 patent/US12209086B2/en active Active
-
2024
- 2024-04-24 JP JP2024070860A patent/JP2024099714A/ja active Pending
- 2024-12-09 US US18/974,196 patent/US20250122196A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230206A1 (ar) | المركبات المثبطة لمستقبل عامل نمو الأرومة الليفية 3 (fgfr3) | |
| MX2025002692A (es) | Derivados de pirazolo[1,5-a]piridina e imidazo[1,2-a]piridina como inhibidores de fgfr3 para el tratamiento del cancer | |
| JOP20180125B1 (ar) | صيغة صيدلانية سائلة ثابتة | |
| CY1109006T1 (el) | Παραγωγα πουρινης ως αναστολεις κινασης | |
| EA202092909A1 (ru) | Новый бензодиазепин, его производные и применение | |
| MY206948A (en) | Aerosol-forming substrate with nitrogen-containing nucleophilic compound | |
| CY1118433T1 (el) | Συνθεσεις oi οποιες περιεχουν θειικη χονδροϊτινη, ναττοκιναση και σουλφυδρυλικες ενωσεις για χρηση στην αγωγη φλεγμονης | |
| BR112018075218A2 (pt) | correia transportadora | |
| EP3784269A4 (en) | ANTI-INTEGRIN LIGANDS AND USES THEREOF | |
| MX2022014126A (es) | Moduladores de enpp1 y usos de los mismos. | |
| ZA202104920B (en) | Methods of treating tyrosine kinase inhibitor-induced diarrhea | |
| MX2019008545A (es) | Estabilidad mejorada de composiciones que contienen inhibidor de la ureasa. | |
| EA201792607A1 (ru) | Подложка, снабженная тонкослойной системой с термическими свойствами, содержащей последний металлический слой и предпоследний окислительный слой | |
| EP3863631A4 (en) | PYRIMIDINE AND PYRAZINE HDAC 1, 2 INHIBITORS | |
| EP4606435A3 (en) | Pharmaceutical composition comprising poorly soluble basic agent | |
| EP4002437A4 (en) | CONTACT WINDOW STRUCTURE, METAL PLUG AND METHOD OF MANUFACTURE THEREOF, AND SEMICONDUCTOR STRUCTURE | |
| TWD208771S (zh) | 連接器組件之部分 | |
| TWD208772S (zh) | 連接器組件之部分 | |
| MX2021000040A (es) | Formulaciones farmaceuticas estables de oximetazolina. | |
| EA201992764A1 (ru) | Пиридиновые и пиразиновые соединения | |
| PL73017Y1 (pl) | Osłona wewnętrzna do profili z podwójnym oszkleniem | |
| PL432346A1 (pl) | Skrzydło okna | |
| JP1778938S (ja) | 目隠し塀用継手 | |
| FR3109729B1 (fr) | Composition expansible | |
| SE1651449A1 (sv) | A wedge for a lead-through system |